reason report
medic set grow pharma guid account headwind
bottom line deliv result behind expect
stock trade all-tim ntm price-to-earnings trough exclud
market correct multipl expans come share
repurchas announc reduct forc cordi turn-
around growth medic patient recoveri busi
stabil gener price environ fundament
busi remain challeng guidanc
larg reflect industri headwind view
maintain op rate reduc pt
pharmaceut divis guid account headwind
perform pharmaceut divis quarter better
expect total pharma oper incom came ahead model
consensu driven brand inflat growth specialti exist
custom nuclear quarter good guid
pharma disappoint pharma oper incom expect
declin high singl low doubl digit y/i basi
less favor y/i declin model
gener deflat rate may appear stabl accord nadac
data believ client renew gener deflationari trend
pose headwind earn assum
believ red oak perform fairli well howev sell-sid
renew rate low brand inflat rate creat risk go forward
re-contract effort part busi manag
highlight continu speak manufactur
negoti regard price distribut servic
manag highlight less brand book
busi tie inventori inventori portion
busi may modest believ fee fee-for-servic
also base list price rate list price inflat slow
top-lin growth rate margin growth also like slow
manag highlight us vast major brand price
increas occur januari even though juli increas
expect januari price increas relev
industri continu work market
transform rel expect unfavor renew
environ sever assum
gener program overal net headwind even though red oak
perform well buy-sid perform view enough
off-set sell-sid price pressur result declin pharma
oper incom
net debt total capit
ep
compani inform leerink partner llc research
revenu present billion dollar
adj dilut ep continu oper
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
well behind leerink consensu
manag highlight signific temporari cost
includ result includ incent compens new
leadership team cost cordi also high exclud
compens cost margin medic would
normal encourag hear cordi top-lin grew
cost tie new inventori manag system weigh result
inventori manag system cost eventu declin
indic cordi return growth
disappoint quarter maintain op overal quarter
disappoint howev maintain outperform rate
stock sever reason first signific one-
time cost includ includ contribut
incent compens medic manag secondli
guidanc alreadi provid includ renew price
pharma client concern on-going gener
deflat headwind guid account industri dynam
thirdli stock trade all-tim low ntm price-to-earnings ratio exclud
market correct sentiment neg
aggress share repurchas program posit result could
caus share pop lastli believ distributor would abl
re-contract manufactur wac list price chang suddenli
account shift market rebat longer allow
negoti manufactur continu believ
manufactur want keep distributor suppli chain
maintain op disappoint quarter maintain
op stock ep estim stand
stock trade rel low ntm price-to-earnings valuat believ
abl turn cordi around mani
divis renew complet believ abl
navig way supply-chain evolut maintain
op reduc pt sentiment pharma
one largest pharmaceut distributor countri one
major cardin busi base pharmaceut distribut
medical-surg suppli distribut ancillari support servic jv
reli redoak drug purchas consortium sourc pharmaceut
product estim redoak gener market share allow sourc
product competit rate serv pharmaci specialti
pharmaci suppli relationship hospit util level
remain somewhat depress industri believ done good job
execut tuck-in acquisit grow footprint faster grow market segment includ
home health medic surgic distribut includ recent acquisit medtron patient
recoveri busi cordi addit though sold distribut busi china
compani retain presenc help sourc higher margin prefer
product add cardin product portfolio believ manag
highli compet like cash-flow characterist busi provid
abil leverag larg fix cost infrastructur recent remov overhang
concern amazon would enter pharma suppli chain recent survey work
show amazon like less threat initi fear core medic distributor
defend moat believ sentiment improv gener brand
drug price trend stabil believ continu solid execut result
time benefit improv sentiment multipl expans current level
result rate cardin outperform
stock trade ep estim well
histor ntm price-to-earnings averag rel ep trade
trade next month expect
share trade ep would put stock
believ amazon overhang overcom like new leadership
ceo mike kaufman stabil gener price trend still face
headwind medic segment believ core busi perform fairli well
maintain op
competit intens custom concentr high compet
op mp well sever smaller medical-
surgic distributor includ owen minor mp inc op
result competit custom buy-sid sell-sid may constantli tri
pressur margin novat premier larg custom present renew risk
lose custom custom put signific margin
pressur compani earn could come pressur
price could declin reform also pose risk price brand-
name drug gener declin time margin could come
pressur addit patient protect afford act health
educ reconcili act implement signific chang industri exampl
increas rebat paid manufactur fee must paid could
advers impact buy-sid margin abl earn addit retail
pharmaci face margin pressur due chang medicaid reimburs chang
awp could pressur compani sell-sid margin
regul extens drug distribut busi subject extens law
regul cover mani aspect compani oper includ fraud abus
law prescript drug pedigre track mani requir mandat
fda state feder law agenc compani requir hold
licens permit oper distribut center
tax posit pose risk oper mani state throughout
world tax law complex within intern perspect
addit ever refin lifo account could advers impact
inform system compani reli inform system within corpor
offic throughout distribut center technolog system complex
requir facilit purchas distribut thousand inventori line-item receiv
process ship order manag bill collect process payment mani
function reason technolog system fail function properli
earn could face substanti risk
acquisit integr could risk perform fair number
acquisit past sever year may continu acquir futur
compani fail integr acquisit onto platform
inform technolog personnel structur issu integr process
compani earn could risk
concentr supplier pose risk supplier make
revenu five supplier gener compani busi contract
typic written one-year basi automat renew year five year given
somewhat high degre concentr among manufactur
depend honor supplier agreement relationship
end deterior manufactur put price pressur
compani earn could risk addit depend raw
materi commod includ nuclear materi price oil impact distribut
econom trend compani global oper impact econom trend
exampl recess could caus patient less will go physician
offic certain procedur done out-of-pocket cost could view substanti
peopl unemploy worri becom unemploy howev
econom trend overal employ improv medical-surg distribut busi
incom statement model fiscal year end june
million
good sold
total revenu
total revenu
sale carefus stock
loss debt extinguish
weight average number share
incom statement model fiscal year end june
million
margin expans bp
margin expans bp
